Assessing liver cancer risk in patients with chronic liver disease using advanced MRI techniques
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
This study is testing new MRI techniques to see if they can help predict the risk of liver cancer in patients with chronic liver disease over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fifth Affiliated Hospital, Sun Yat-Sen University Academic / other |
| Locations | 1 site (Zhuhai, Guangdong) |
| Trial ID | NCT06060769 on ClinicalTrials.gov |
What this trial studies
This study utilizes multi-parameter magnetic resonance imaging (MRI) techniques, including T1 mapping, T2 mapping, T1ρ, and elastography, to quantitatively assess the risk of hepatocellular carcinoma (HCC) in patients with cirrhosis. It involves both retrospective and prospective data collection from patients, who will be monitored over a five-year period to determine the development of liver cancer. The study aims to compare clinical characteristics, laboratory tests, and imaging parameters between patients who develop HCC and those who do not, ultimately creating a predictive nomogram for HCC risk based on these variables.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with chronic liver disease classified as Child-Pugh A or B and who meet specific high-risk criteria for liver cancer.
Not a fit: Patients who are unable to undergo MRI scanning due to claustrophobia or other medical conditions, as well as those who have had prior liver surgery or significant comorbidities, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable method for early detection of liver cancer in high-risk patients, potentially improving patient outcomes.
How similar studies have performed: While the use of MRI in assessing liver cancer risk is established, this specific multi-parameter approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Aged over 18 years old; 2. Liver function Child-Pugh classification A or B; 3. Patients with chronic liver disease who meet the diagnostic criteria for high-risk groups of liver cancer in the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)"; 4. Equipped with Gd-EOB-DTPA enhanced MRI scan images, including T1 mapping, T2 mapping, T2\* mapping, T1ρ and other sequences; 5. With 5-year follow-up data. Exclusion Criteria: * 1\. Patients who are unable to undergo MRI scanning due to claustrophobia, abnormal renal function, etc.; 2. Patients who have undergone liver surgery in the past; 3. Patients with major diseases such as heart failure and tumors.
Where this trial is running
Zhuhai, Guangdong
- Yaqin, Zhang — Zhuhai, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Yaqin Zhang, MD, Ph.D
- Email: zhyaqin@mail.sysu.edu.cn
- Phone: 13719282895
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.